title: Catechol-O-methyltranferase gene expression is associated with response to citalopram in obsessive-compulsive disorder.
abstract: OBJECTIVE
  To determine whether polymorphisms of the dopamine D(2) receptor (DRD2) and catechol-O-methyl-transferase (COMT) receptor genes affect the efficacy of quetiapine addition to citalopram in patients with OCD.
  
  
  METHODS
  Sixty-four drug-free or drug-naïve patients meeting DSM-IV criteria for OCD were randomized to 10 weeks double-blind treatment with citalopram (60 mg/day) with quetiapine (300 -450 mg/day) or with placebo. The change from baseline to endpoint on the total Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) and the response to treatment were the primary outcome measures. Response was defined as a 25% decrease in Y-BOCS score. Responders and nonresponders were stratified according to DRD2 TaqI A and COMT Val(158)Met genotypes.
  
  
  RESULTS
  No significant differences in genotype distribution or allele frequencies of the COMT or DRD2 receptor were found between responders and nonresponders to citalopram with quetiapine. However, nearly half of responders to citalopram with placebo carried the Met/Met (48%) genotype of the COMT polymorphism compared to none of the nonresponders (χ(2) = 10.06, df = 2, P = 0.007).
  
  
  CONCLUSIONS
  The Met allele load of the COMT receptor gene was associated with response to 10 weeks of treatment with citalopram in drug-free or drug-naïve OCD patients.
authors.affiliation: Department of Psychiatry, AMC, University of Amsterdam, Amsterdam, The Netherlands.
authors.forename: Nienke C C
authors.initials: NC
authors.lastname: Vulink
authors.forename: Herman G M
authors.initials: HG
authors.lastname: Westenberg
authors.forename: Filip
authors.initials: F
authors.lastname: van Nieuwerburgh
authors.forename: Dieter
authors.initials: D
authors.lastname: Deforce
authors.forename: Sjoerd B A H A
authors.initials: SB
authors.lastname: Fluitman
authors.forename: Jantien S C
authors.initials: JS
authors.lastname: Meinardi
authors.forename: Damiaan
authors.initials: D
authors.lastname: Denys
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D002394:Catechol O-Methyltransferase / Q000235:genetics*; D015283:Citalopram / Q000627:therapeutic use*; D003987:Dibenzothiazepines / Q000627:therapeutic use; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D015870:Gene Expression / Q000235:genetics*; D005787:Gene Frequency / Q000235:genetics; D005838:Genotype; D006801:Humans; D008297:Male; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000235:genetics; D011110:Polymorphism, Genetic / Q000235:genetics*; D000069348:Quetiapine Fumarate; D017448:Receptors, Dopamine D2 / Q000235:genetics; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D002394:Catechol O-Methyltransferase; D015283:Citalopram; D003987:Dibenzothiazepines; D000069348:Quetiapine Fumarate; D017448:Receptors, Dopamine D2; D017367:Selective Serotonin Reuptake Inhibitors